DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-6236 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Drugs For Chronic Obstructive Pulmonary Disorder Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET
7.1 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Aquinox Pharmaceuticals
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 GSK
16.3 Boehringer Ingelheim
16.4 Ario Pharma
16.5 BioMarck Pharmaceuticals
16.6 Asmacure
16.7 Novartis
16.8 Almirall
16.9 AstraZeneca
16.10 Astellas Pharma
16.11 Ache Laboratorios Farmaceuticos
16.12 Teva Pharmaceuticals
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeShort-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
By Application
GOLD 1: FEV1 ? 80%
GOLD 2: 50% ? FEV1 < 80%
GOLD 3: 30% ? FEV1 < 50%
GOLD 4: FEV1 < 30%
Companies
Aquinox Pharmaceuticals
GSK
Boehringer Ingelheim
Ario Pharma
BioMarck Pharmaceuticals
Asmacure
Novartis
Almirall
AstraZeneca
Astellas Pharma
Ache Laboratorios Farmaceuticos
Teva Pharmaceuticals
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.